Birch Grove Capital LP - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAA6. A total of 36 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.5%.

Quarter-by-quarter ownership
Birch Grove Capital LP ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q2 2021$13,500,000
+16.5%
15,003,000
+7.1%
6.56%
+30.4%
Q1 2021$11,590,000
+46.1%
14,003,000
+40.0%
5.03%
+21.6%
Q4 2020$7,934,000
+116.9%
10,003,000
+122.1%
4.14%
+108.9%
Q3 2020$3,658,0004,503,0001.98%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q2 2021
NameSharesValueWeighting ↓
SILVERBACK ASSET MANAGEMENT LLC 12,851,000$12,016,0002.95%
Context Capital Management, LLC 3,000,000$2,804,0002.24%
Man Investments (CH) AG 3,000,000$2,798,0001.76%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 42,500,000$39,540,0001.52%
MACKAY SHIELDS LLC 17,069,000$15,982,0000.73%
HIGHFIELDS CAPITAL MANAGEMENT LP 73,035,000$68,425,0000.63%
WOLVERINE ASSET MANAGEMENT LLC 42,307,000$39,554,0000.61%
LINDEN ADVISORS LP 14,122,000$13,194,0000.49%
GLG LLC 9,100,000$8,486,0000.47%
Jabre Capital Partners S.A. 3,400,000$3,179,0000.38%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders